HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 23 February 2017

NICE Health Apps briefings

From PMLive:

“NICE is preparing to apply its healthcare technology assessment (HTA) experience to health-focused mobile applications, and will start publishing a series of non-guidance briefings in the coming year.

The new Health App Briefings from the UK's cost-effectiveness watchdog are designed to set out the evidence and data for healthcare professionals and prospective app users with the aim of determining the efficacy of these digital health regimens in a real-world setting.

The programme is currently in mid-way through its pilot stage, with this due to come to a close in March 2017.”

Image: #febphotoaday by Kenny Louie

Wednesday, 22 February 2017

MSc Economics and Health Economics teaching

Spring semester teaching has just started.  This semester’s modules are:
  • Applied Microeconometrics
  • Health Service Research Methods
  • Valuing the Benefits of Health Care
Students also take an optional module from a wide ranging list, with the two most popular being Public Economics and Public Policy Evaluation

Further details of the programme can be found here.

Monday, 20 February 2017

NIHR Fellowships

Four members of staff in ScHARR were successful in the most recent round of the NIHR Fellowship Programme and have been offered a prestigious NIHR Doctoral Research Fellowship:

Alexis Foster (Design, Trials and Statistics)
Kelly Mackenzie (Public Health)
Rachid Rafia (Health Economics and Decision Science)
Benjamin Kearns (Health Economics and Decision Science)

Rachid Rafia’s fellowship aims to develop a methodological framework to inform the choice of analytic approaches for modelling cancer therapies subject to the nature of data available and to guide decision-making based on these models. Mathematical models are commonly used to predict patients’ quality of life, how long they are likely to live, and the cost to the NHS if they receive a new treatment. These models are needed because clinical trials do not always provide enough information about all of these outcomes. However, different approaches are used inconsistently which may result in different predictions. This could lead to inconsistent decision-making and have a significant impact on patients and the NHS. Therefore there is a need for more consistency in the way economic evaluations are conducted.

Benjamin Kearns’ fellowship will look at producing guidance on good practice methods for predicting future outcomes in health technology assessment (HTA). HTAs can be a key evidence source for decision makers when deciding if they should be paying for health technologies. Key outcomes in HTA are the costs to the healthcare system and the benefits to patients. Typically, decision makers need to know what these outcomes will be over a patient’s lifetime, but only have evidence for a limited time period. Hence methods for predicting future outcomes are required. Ben’s fellowship shall build on previous and on-going work to produce good-practice guidance to assist with producing and communicating predictions of the future.

Friday, 17 February 2017

Mapping good practice guidelines

ISPOR guidelines have just been published, with the catchy title of “Mapping to Estimate Health-State Utility from Non–Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report”.  T-shirts are not yet available.

Allan Wailoo and Monica Hernandez-Alava from HEDS are two of the principal authors….

“The recommendations cover all areas of mapping practice: the selection of data sets for the mapping estimation, model selection and performance assessment, reporting standards, and the use of results including the appropriate reflection of variability and uncertainty. This report is unique because it takes an international perspective, is comprehensive in its coverage of the aspects of mapping practice, and reflects the current state of the art.”

Thursday, 16 February 2017

MSc Health Economics and Decision Modelling

Spring semester teaching has just started.  This semester’s modules are:
  • Advanced Simulation Methods    
  • Medical Statistics and Evidence Synthesis    
  • Operational Research Techniques in Health Resources Allocation    
  • Valuing the Benefits of Health Care

Further details of the programme can be found here.

Image: Snowdrops 2 by Jim Barter

Tuesday, 14 February 2017

January’s CEAs.....

Our quick search for CEA’s published in January uncovered 38 articles.   In the right-hand column of this blog is a CEA Archive, which includes our CEA search results by month.  Below are those in our areas of interest.
  • Lapointe-Shaw L, Voruganti T, Kohler P, Thein HH, Sander B, McGeer A. Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients. European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology. 2017.
  • Wong KM, Ding K, Li S, Bradbury P, Tsao MS, Der SD, et al. A Cost-Effectiveness Analysis of Using the JBR.10-Based 15-Gene Expression Signature to Guide Adjuvant Chemotherapy in Early Stage Non-Small-Cell Lung Cancer. Clinical lung cancer. 2017;18(1):e41-e7.
  • Yang MC, Tan EC, Su JJ. Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human vaccines & immunotherapeutics. 2017;13(1):81-9.
  • Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA. A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK. The European journal of health economics : HEPAC : health economics in prevention and care. 2017.

Monday, 13 February 2017

International HTA teaching

The spring semester has just started.  This semester’s modules are:
  • International Healthcare Systems and Reimbursement
  • Cost-effectiveness Modelling in International HTA
  • Building Cost-effectiveness Models for HTA    
  • Utility and Patient-reported Outcomes Data in HTA
  • Image: Medicine cost by Images Money
  • Pharmaceutical Pricing

These modules can contribute toward a Masters, Postgraduate Diploma or Certificate in International HTA, Pricing and Reimbursement.  Alternatively, Cost-effectiveness Modelling in International HTA and Building Cost-effectiveness Models for HTA, form 50% of Postgraduate Certificate in Cost Effectiveness Modelling for HTA.

Thursday, 9 February 2017

Job in HEDS

We are looking for a Co-ordinator Health Economics and Outcome Measurement (HEOM) Programme within the Collaboration for Leadership in Applied Health Research and Care for Yorkshire and the Humber (CLAHRC YH).

The CLAHRC is a collaboration between the Universities of Sheffield, Bradford and York, and hosted by the Sheffield Teaching Hospital. Whilst, the HEOM Theme is looking at ways to improve patient care by providing healthcare decision
makers with the best evidence possible to make the best choices for their patients.

Image: Give me a better job by duncan c

Closing date is the 20th February 2017.  Further details are available here.

Wednesday, 8 February 2017

HEDS on Twitter gets its 1000th Follower!

Our HEDS Twitter account @ScHARRHEDS has just got its 1000th follower. We have been on Twitter since 2011 and it is a great platform for us to share our latest news, research and courses as well as share insights from colleagues, peers and organisations in our wide sphere of work. If you want to stay up to date with all the good stuff we share then get onto Twitter and follow us, you never know, we might even follow you back ;-) You can also follow HEDS colleagues and projects as well as ScHARR Twitter accounts by subscribing to these lists.



Tuesday, 7 February 2017

Quarterly summary of ScHARR Reports

To help our readers keep track of what we do, we provide a monthly list of journal publications, news of new projects, quarterly summaries of our discussion papers and announcements of DSU reports.  To add to this, we are now producing a quarterly summary of all our public and third sector reports.  Here’s our first one, covering October – December 2016.  If you require any further information on any of these, contact the ScHARR Library.

  • Evolocumab for treating hyperlipidaemia and mixed dyslipidaemia (excluding homozygous familial hypercholesterolaemia) [ID765] (2016)
  • Cabazitaxel for treating hormone-relapsed metastatic prostate cancer after a docetaxel-containing regimen (review of TA255)[ID889] (2016)
  • Adalimumab for treating moderate to severe hidradenitis suppurativa [ID812] (2016)
  • The clinical and cost-effectiveness of the LightCycler SeptiFast Test MGRADE, SepsiTest and IRIDICA BAC BSI assay for rapidly identifying bloodstream bacteria and fungi: a systematic review and economic evaluation. (2016)

  • DSU report: The use of real world data for the estimation of treatment effects in NICE decision making (June 2016, updated December 2016)
  • TSD18: Methods for population-adjusted indirect comparisons in submissions to NICE (December 2016)

  • Mukuria C, Peasgood T, Rowen D, Brazier J.  An empirical comparison of well-being measures used in the UK.  Policy Research Unit in Economic Evaluation of Health and Care Interventions. Universities of Sheffield and York. EEPRU Research Report 048 (November 2016). 

  • Evaluating Self Management in Diabetes (ESMiD) Revised Final Report for the Health Foundation (April 2016). Sponsor: The Health Foundation
  • A model to evaluate the cost effectiveness of condom distribution (CD schemes), developed for NICE public health guidance on condom distribution schemes and sexually transmitted infections (STIs) May 2016. Sponsor: NICE